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 INTRODUCTION 
 Intrahepatic cholestasis of pregnancy (ICP), also known as 
obstetric cholestasis, occurs in  ~ 1 in 150 UK pregnancies. Mater-
nal symptoms of the disease include pruritus, raised serum bile 
acids, and deranged liver function tests ( 1 – 4 ). Liver transami-
nases can be increased as much as 100-fold, but the bilirubin 
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 OBJECTIVES:  Intrahepatic cholestasis of pregnancy (ICP) has a complex etiology with a signifi cant genetic 
component. Heterozygous mutations of canalicular transporters occur in a subset of ICP cases and 
a population susceptibility allele (p.444A) has been identifi ed in  ABCB11 . We sought to expand our 
knowledge of the detailed genetic contribution to ICP by investigation of common variation around 
candidate loci with biological plausibility for a role in ICP ( ABCB4 ,  ABCB11 ,  ABCC2 ,  ATP8B1 , 
 NR1H4 , and  FGF19) . 
 METHODS:  ICP patients ( n  =  563) of white western European origin and controls ( n  =  642) were analyzed in a case –
 control design. Single-nucleotide polymorphism (SNP) markers ( n  =  83) were selected from the HapMap 
data set (Tagger, Haploview 4.1 (build 22)). Genotyping was performed by allelic discrimination assay on 
a robotic platform. Following quality control, SNP data were analyzed by Armitage ’ s trend test. 
 RESULTS:  Cochran – Armitage trend testing identifi ed six SNPs in  ABCB11 together with six SNPs in  ABCB4 
that showed signifi cant evidence of association. The minimum Bonferroni corrected  P value for 
trend testing  ABCB11 was 5.81 × 10   −  4 (rs3815676) and for  ABCB4 it was 4.6 × 10   −  7 (rs2109505). 
Conditional analysis of the two clusters of association signals suggested a single signal in  ABCB4 
but evidence for two independent signals in  ABCB11 . To confi rm these fi ndings, a second study was 
performed in a further 227 cases, which confi rmed and strengthened the original fi ndings. 
 CONCLUSIONS:  Our analysis of a large cohort of ICP cases has identifi ed a key role for common variation around 
the  ABCB4 and  ABCB11 loci, identifi ed the core associations, and expanded our knowledge of ICP 
susceptibility. 
 SUPPLEMENTARY MATERIAL is linked to the online version of the paper at  http://www.nature.com/ajg 
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 ICP and Genetic Variation at Candidate Loci 
level is usually normal or mildly raised. Fetal consequences of 
ICP include spontaneous and iatrogenic preterm labor, meco-
nium-stained amniotic fl uid, fetal distress, and intrauterine death 
( 5 – 8 ). Approximately 80 % of patients present aft er 30 weeks of 
gestation and diagnosis is routinely confi rmed by elevated serum 
bile acid concentrations and liver function tests ( 9 ). Higher levels 
of fasting and nonfasting serum bile acids (  >  40  μ M ) have been 
associated with increased risk of adverse pregnancy outcomes 
including spontaneous preterm labor, meconium passage, still-
birth, and prolonged admission to the neonatal unit ( 8,10 ). Severe 
ICP, defi ned by maternal serum bile acid levels of  ≥ 40  μ M , aff ects 
1 in 1,000 pregnancies in the United Kingdom ( 10 ). Treatment 
is usually with ursodeoxycholic acid, to which  ~ 70 % of patients 
respond with improvement in maternal liver function tests, bile 
acids, and pruritus ( 11,12 ). It is currently not known whether 
ursodeoxycholic acid treatment reduces the risk of adverse preg-
nancy outcome, although the results of two recent studies were 
encouraging ( 12,13 ). Th e impact of ICP for the off spring was fur-
ther highlighted by a recent study that reported increased rates of 
obesity and dyslipidemia in the 16-year-old off spring of aff ected 
women ( 14 ). 
 ICP has a complex, multifactorial etiology with hormonal, envi-
ronmental, and genetic infl uences. Considerable evidence for a 
genetic predisposition to this disease comes from signifi cant famil-
ial clustering ( 15,16 ), population-specifi c risk diff erences ( 17 ), and 
increased risk with an aff ected fi rst-degree relative ( 18 ). Genes 
mutated in progressive familial intrahepatic cholestasis (PFIC) 
and the related condition benign recurrent intrahepatic cholestasis 
(BRIC), namely  ABCB4 ,  ABCB11 , and  ATP8B1 , have been impli-
cated in the pathogenesis of ICP in a number of diff erent studies. 
Initial studies identifi ed heterozygous mutations of the phosphati-
dyl choline fl oppase  ABCB4 (MDR3) in familial ( 19 ) and sporadic 
( 20 ) cases. Homozygous mutations of this gene cause a severe 
childhood-onset liver disease, PFIC3 ( 21 ). Th ese fi rst studies of 
the genetics of ICP susceptibility were confi rmed and expanded 
by a number of subsequent studies ( 22 – 24 ). Mutations in  ABCB4 
cause a number of other biliary disorders, including drug-induced 
cholestasis ( 25 ) and low phospholipid-associated cholelithiasis 
( 26 ). A small single-nucleotide polymorphism (SNP) / haplotype 
study of common variation around this locus in 52  “ severe ” ICP 
cases with serum bile acid levels of   >  40  μ M provided additional 
evidence for a role in ICP susceptibility ( 27 ). Hence,  ABCB4 muta-
tions and variation are linked to a spectrum of cholestatic disease 
of varying severity. 
 ABCB11 (the bile salt export pump), another member of the 
ABC transporter superfamily, is the high-affi  nity liver-specifi c 
transporter responsible for the export of conjugated bile acids into 
the canaliculus ( 28 ). Homozygous loss-of-function mutations of 
this gene cause the cholestatic diseases PFIC2 and BRIC2 ( 29 ). 
Th e role of genetic variation at this locus in ICP susceptibility has 
recently been explored in detail, with several recurrent mutations 
identifi ed, together with the confi rmation of the p.444A variant as 
a population susceptibility allele ( 30 ). Further analysis of an Italian 
cohort has further established  ABCB11 variation as playing a role 
in ICP susceptibility ( 31 ). 
 Acting together with ABCB4, this transporter is responsible for 
bile salt-dependent bile fl ow. Th e phosphatidyl choline fl opped by 
ABCB4 complexes with bile salts exported by ABCB11 and cho-
lesterol transported by ABCG5 / G8 to form mixed micelles in the 
canalicular tree and protect the ductal epithelium from the deter-
gent action of the bile salts . 
 Th e involvement of another familial cholestasis gene,  ATP8B1 
(mutated in PFIC1 / BRIC1), has not been established defi nitively. 
Th is protein is proposed to function as a phosphatidyl serine 
fl ippase in the canalicular membrane and has been studied to a 
limited extent in ICP cohorts ( 32,33 ). Furthermore, recent work 
has identifi ed a functional interdependence with the ABCB4 pro-
tein ( 34 ). 
 Bile salt-independent bile fl ow is primarily the result of another 
transporter,  ABCC2 (MRP2 (multidrug resistance-related protein 
2)), that transports bilirubin and other organic anions (including 
some bile acids) across the canalicular membrane ( 35 ). Involve-
ment of genetic variation around  ABCC2 in ICP has been reported 
in South American populations ( 36 ). 
 Th e activity of the transporters responsible for bile formation 
is regulated by the principal bile acid sensor FXR ( NR1H4 ), and 
functional variation of this receptor has been identifi ed in ICP 
( 37 ). FXR acts as the master regulator of bile acid homeostasis by 
sensing intracellular concentrations of bile acids and regulating 
their metabolism and transport via modulation of promoter activ-
ity in key genes ( 38,39 ). In addition, key feedback signaling from 
the gut is performed by  fi broblast growth factor 19 ( FGF19 ). Th is 
is a peptide hormone released by enterocytes via FXR-mediated 
transcriptional activation. It downregulates hepatocyte CYP7A1 
activity (via FGFR4 / β -klotho-mediated transduction) and hence 
bile acid synthesis ( 40 ) and is vital in controlling appropriate levels 
of hepatic FXR activity. 
 In addition to  ABCB4 and  ABCB11 , these other loci represent 
biologically plausible candidates for a role in ICP susceptibility. Of 
note, a number of small studies in a variety of populations have 
examined other loci postulated to play a role in ICP susceptibil-
ity (reviewed in Dixon and Williamson ( 17 )) without providing 
defi nitive evidence of involvement. Although several of the genes 
have already been demonstrated to play a role in ICP in Caucasians 
( ABCB4 ,  ABCB11 , and  NR1H4 ), there is still a paucity of infor-
mation concerning the contribution of other key genes ( ABCC2 , 
 ATP8B1 , and  FGF19 ) in the etiology of ICP. 
 In order to clarify and expand the genetic factors known to play a 
role in ICP, we sought to investigate the common variation around 
the six candidate loci described above in a large ICP cohort and 
further investigate these fi ndings in a second cohort. 
 METHODS 
 Patients (initial cohort ) 
 A cohort  of 563 ICP patients of white western European origin 
together with 642 controls of the same origin from the Rotunda 
Th rombophilia study ( 41 ) were analyzed in a case – control design. 
Th is cohort is an extension of our previously described cases (27) 
and includes all previously studied women. For this study, fasting 
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and nonfasting maternal serum bile acid levels were used to make 
the diagnosis of ICP as it was not possible to obtain fasting sam-
ples from all women attending antenatal clinics. 
 Th is study conformed to the guidelines outlined by the 1975 
Declaration of Helsinki and permission was obtained from the 
Ethics Committees of the Hammersmith Hospitals NHS Trust, 
London (REC 97 / 5197), the Ethics Committee of the Faculty 
of Medicine at the University of G ö teborg, University Hospital 
Aachen, University Hospital Dusseldorf, and the Ethics committee 
of the Rotunda Hospital, Dublin. 
 All ICP patients were diagnosed on the basis of clinical symp-
toms in combination with routine laboratory investigations, as 
described previously ( 27,33 ). ICP was diagnosed in pregnant 
women with pruritus without evidence of rash apart from derma-
titis artefacta, and confi rmation of the diagnosis was made with 
raised serum liver transaminases and / or bile acids. Women were 
excluded if another hepatic disorder was diagnosed following 
identifi cation of abnormal hepatitis serology (hepatitis A, B, or C), 
or extrahepatic biliary obstruction following ultrasound examina-
tion. Genomic DNA was extracted from buff y coats prepared from 
EDTA blood samples using standard methods, principally with the 
Qiagen blood mini kit (Qiagen, Crawley, UK). DNA purity and 
concentration were determined with an ND-1000 Nanodrop spec-
trophotometer (Th ermofi sher Scientifi c, Loughborough, UK) . 
 Polymorphisms around the six candidate loci ( ABCB4 ,  ABCB11 , 
 NR1H4 ,  ABCC2 ,  ATP8B1 , and  FGF19) drawn from the HapMap 
database (version 2, release 22) were analyzed with Haploview 
(v4.1, Broad Institute, Boston, MA). Markers were selected from 
the genomic region of each locus including 5  kb up- and down-
stream of the coding region. Following fi ltering of the marker set 
to exclude rare alleles (minor allele frequency   <  0.05) the tagger 
algorithm was used to select markers from the HapMap database. 
Th is identifi ed a set of SNPs that effi  ciently captured genetic varia-
tion at each locus so that all untyped variants had high correlation 
( R 2   >  0.8) with one member of the typed set . In cases where mark-
ers had been previously reported to be associated with ICP, these 
markers were force-included in the selection algorithm. 
 In total, 83 markers were identifi ed encompassing the six loci as 
follows: 23 around  ABCB11 , 14 around  ABCB4 , 11 around  ABCC2 , 
22 around  ATP8B1 , 6 around  NR1H4 , and 5 around  FGF19 
( Supplementary Table S1 online). 
 Primers were designed for each selected SNP using  “ Primer 
Picker ” (KBioscience, Hoddesdon, UK). Genotyping was under-
taken using a competitive allele-specifi c PCR SNP genotyping sys-
tem utilizing FRET quencher cassette oligonucleotides (KASPar, 
KBioscience) with DNA concentrations adjusted as appropriate. 
 Statistical analysis 
 Provided there was no evidence of departure from Hardy – 
Weinberg equilibrium (Pearson ’ s  χ 2 test), SNP data were analyzed 
by Armitage ’ s trend test (PLINK v1.07; see ref. ( 42 )). Subsequently, 
the data were tested for a diff erence in haplotype frequencies 
between cases and controls by  χ 2 tests (R v2.10.1, Haplostats V1.4, 
see ref. ( 43 )) at each locus. All  P values were subjected to Bonfer-
roni correction for multiple testing by multiplying uncorrected 
 P values by the number of independent tests performed (78 for 
SNP testing and 6 for haplotype analysis). Following correction, 
 P values of   <  0.05 were considered signifi cant. 
 Th e association signals were further analyzed using logistic 
regression performed in R. In particular, we tested each SNP con-
ditional on each other SNP using likelihood ratio tests to deter-
mine whether multiple signals were present at each associated loci. 
Heat maps, in which color indicates the strength of evidence for 
association, were used to visualize these results. 
 Second cohort analysis 
 Th e SNPs identifi ed by this analysis, namely rs2109505 in  ABCB4 
together with rs7757650 and rs3815676 in  ABCB11 , were then 
tested in a second cohort. Th us, 227 further ICP cases, identifi ed 
as part of on-going recruitment, were collected in the same way 
as the fi rst cohort (see above), together with cases from Kings 
College Hospital (ethics REC 02 / 03 / 033), and DNA extracted and 
SNP genotyping performed as described above. None of these 
cases have been reported in our previous genotyping studies. 
 Association was tested using this cohort alone, and then in 
a combined analysis of the three SNPs in each cohort, with the 
statistical tests described above. 
 RESULTS 
 In total, 78 markers passed quality control and Hardy – Weinberg 
testing and were used in association analysis of the two cohorts. 
Association analysis with the Armitage trend test identifi ed six 
SNPs in  ABCB11 together with six SNPs in  ABCB4 showing signif-
icant evidence for association ( Table 1 ). Th e strongest association 
signals were seen with rs2109505 in  ABCB4 and with rs7577650 
in  ABCB11 . No SNPs from the other four loci showed evidence of 
association ( Supplementary Table S1 ). 
 Th e data set was investigated further by haplotype analysis across 
each of the six loci, which identifi ed signifi cant diff erences in fre-
quencies between cases and controls for  ABCB11 and  ABCB4. No 
other signifi cant diff erences in haplotype frequencies across the 
other loci ( ABCC2 ,  ATP8B1 ,  NR1H4 , and  FGF19 ) were identifi ed 
( Supplementary Table S2 ). 
 ABCB11 
 HapMap analysis identifi ed 23 tagging polymorphisms that passed 
quality control. Association analysis of these markers subsequent 
to genotyping identifi ed six markers signifi cantly associated with 
altered risk for ICP: rs228762, rs2058996, rs7605199, rs3815676, 
rs3814382, and rs7577650 ( Table 1 ). Th e most strongly associated 
marker was rs7577650 (trend test corrected  P  =  1.8 × 10   −  4 ). 
 ABCB4 
 HapMap analysis identifi ed 14 polymorphisms that passed qual-
ity control. Association analysis of these markers subsequent to 
genotyping identifi ed six markers signifi cantly associated with 
altered risk for ICP: rs2097937, rs31676, rs1149222, rs4148826, 
rs2109505, and rs2302386 ( Table 1 ). Th e most strongly associated 
marker was rs2109505 ( P  =  4.6 × 10   −  7 ). 
© 2014 by the American College of Gastroenterology The American Journal of GASTROENTEROLOGY
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 ABCC2 ,  ATP8B1 ,  NR1H4 , and  FGF19 
 Around these loci, HapMap analysis identifi ed 41 polymorphisms 
but none showed signifi cant evidence for association in our cohort 
( Supplementary Table S1 ). Th e previously reported  ABCC2 asso-
ciation ( 36 ) was not detected in this cohort. 
 Haplotype analysis 
 Th e data set was investigated further by haplotype analysis across 
all six loci ( Supplementary Tables S2 and S3a and b ). Signifi cant 
diff erences were identifi ed in haplotype distributions between 
cases and controls for  ABCB11 (global corrected  P value 0.02) and 
 ABCB4 (global corrected  P value 5.76 × 10   −  5 ). 
 Conditional analysis of association and second cohort analysis 
 Heat maps were generated using conditional analysis with logis-
tic regression to visualize the patterns of evidence for associa-
tion across the locus. Th is analysis showed that the association 
signal in  ABCB4 was explained by the SNP rs2109505, with no 
evidence for further signals (( P  >  0.05;  Figure 1 ). Th is is shown 
in the diagram by the red horizontal signal for this SNP (i.e., sig-
nifi cant evidence for association regardless of which other SNPs 
are corrected for) and the white column ( “ corrected for ” ) for this 
SNP, indicating no other signifi cant signal when the eff ect of this 
SNP is corrected for. In contrast, analysis of the associated SNPs 
in  ABCB11 identifi ed evidence for two independent signals, 
at the SNPs rs3815676 and 7577650: each remains signifi cant 
( P  <  10   −  4 ) correcting for the other, or any other SNP at this locus 
( Figure 2 ). In the heat map, the strong red color again indicates 
evidence for association, but in this case the  “ corrected for ” 
column shows evidence of the second signal, indicated by the 
darker red block. Th e key SNPs identifi ed by this analysis were 
genotyped in the second cohort. Using the controls from the fi rst 
cohort for comparison, the association with each SNP was con-
fi rmed and when analyzed together the combined cohort indi-
cated strong evidence for association ( Table 2 ). Th e odds ratios 
calculated for the trend tests are allelic and, as ICP is rare, are 
approximately equivalent to the corresponding relative risk. Th us, 
for the association with rs3825676 (a rare SNP compared with 
the majority studied), the odds ratio indicate a risk of ICP that 
is 3.79 times higher in the homozygote than the heterozygote 
(with a corresponding reduction in risk in the other homozygote 
genotype.). For the other SNPs analyzed using this test, the same 
principle applies. Hence, for the much commoner SNP rs7577650, 
the homozygotes have a 1.4 times change in risk for ICP, and for 
rs2109505 in  ABCB4 (again a much commoner SNP), the odds 
ratio shows a change in risk of 2.06-fold. 
 DISCUSSION 
 We present here the results of the analysis of six candidate loci 
for susceptibility to ICP. We have extended and expanded prior 
studies on these biologically plausible candidates and confi rmed 
key roles for variation around two of the loci studied by identi-
fying groups of strongly associated polymorphisms. We have 
demonstrated signifi cant association of SNPs and haplotypes of 
the key transporters responsible for bile formation, the bile salt 
export pump  ABCB11 , and the phosphatidyl choline fl oppase 
 ABCB4 , with ICP. Aft er determining the key association signals 
 Table 1 .  Single-nucleotide polymorphisms of  ABCB11 and  ABCB4 showing signifi cant evidence of association with ICP (trend test) 
 dbSNP   Location (bp)  MAF (ICP)  MAF (C)  OR (95 % CI)  P value  P (corr) 
 ABCB11 
  rs2287622  169,538,574  0.33  0.40  1.39 (1.17 – 1.64)  0.000159  0.012363 
  rs2058996  169,542,195  0.38  0.46  1.39 (1.18 – 1.65)  0.000145  0.011287 
  rs7605199  169,564,700  0.47  0.45  1.36 (1.16 – 1.6)  0.000374  0.029172 
  rs3815676  169,578,625  0.015  0.052  3.32 (1.93 – 5.71)  7.45 × 10   −  6  0.000581 
  rs3814382  169,597,234  0.45  0.38  1.35 (1.15 – 1.60)  0.000511  0.039874 
  rs7577650  169,599,456  0.31  0.40  1.52 (1.28 – 1.80)  2.4 × 10   −  6  0.00018 
 ABCB4 
  rs2097937  86,868,839  0.16  0.22  1.50 (1.22 – 1.86)  0.00018  0.014017 
  rs31676  86,907,816  0.16  0.24  1.45 (1.15 – 1.83)  1.72 × 10   −  6  0.000134 
  rs1149222  86,911,711  0.14  0.27  1.63 (1.31 – 2.02)  8.66 × 10   −  6  0.000676 
  rs4148826  86,912,355  0.11  0.20  1.95 (1.54 – 2.45)  1.56 × 10   −  8  1.22 × 10   −  6 
  rs2109505  86,917,342  0.11  0.20  1.98 (1.57 – 2.49)  5.9 × 10   −  9  4.6 × 10   −  7 
  rs2302386  86,929,880  0.078  0.14  1.98 (1.51 – 2.60)  2.95 × 10   −  7  2.3 × 10   −  5 
 bp, base pairs; C, control; CI, confi dence interval; dbSNP, single-nucleotide polymorphism database; ICP, intrahepatic cholestasis of pregnancy; MAF, minor allele fre-
quency; OR, odds ratio;  P (corr),  P value corrected for multiple testing . 
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variant rs2109505 (c.711 A  >  T, p.I237I) was the most signi fi cant, 
identifi ed as the key signal by conditional analysis and con-
fi rmed in the second cohort. Th is association has been previously 
reported in smaller population-based studies in ICP ( 22,27 ).  In 
silico analysis of splicing using predictive tools together with 
mini-gene construct mRNA analysis in COS-1 cells failed to 
identify an eff ect of this variant on ABCB4 splicing (data not 
shown). 
with conditional analysis, these fi ndings were confi rmed in a sec-
ond cohort. 
 Heterozygous mutant alleles of  ABCB4 have been described 
in a spectrum of cholestatic disease, including ICP ( 17 ). Our 
analysis has demonstrated strong association at this locus, 
confi rming that common polymorphisms together with rare 
mutations ( 16,17,19,20 ) in this region are implicated in ICP. 
Of the six polymorphisms showing association, the synonymous 
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 Figure 1 .  Heat map showing conditional analysis of association signals at the  ABCB4 locus. Each row plots the  P value for the row single-nucleotide poly-
morphism (SNP), corrected for the column SNP, with color intensity indicating the size of the  P value by order of magnitude units, hence 5 indicates a 
 P value of   <  10   −  5 . Thus, the map explores the independent effect of each SNP by removing the effects of each of the others in turn to determine if a single 
or multiple association signals are present. 
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 Th e contribution of synonymous mutations to disease suscepti-
bility via a number of diff erent mechanisms is being increasingly 
realized ( 44 ); however, the possibility remains that this association 
is because of linkage disequilibrium between rs2109505 and an 
unknown causative variant. 
 Th e association seen at the  ABCB11 locus (the bile salt export 
pump) expands the role of this gene in ICP. We and others previ-
ously identifi ed rare heterozygous mutant alleles in ICP, together 
with an association with rs2287622 (the p.444A polymorphism) 
( 30,45,46 ). In this study we have extended the analysis across 
the gene, and unraveled the genetic architecture underlying sus-
ceptibility at this locus. Importantly the association signal in the 
cases, confi rmed in the expanded cohort with the second group of 
patients, is composed of two signals, the major one from rs7577650 
but with rs3815676 contributing independently to risk, although 
at a relatively low frequency. Th e p.444A variant remains associ-
ated with disease but our comprehensive analysis suggests that a 
diff erent marker drives this association, namely rs7577650. Th ese 
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 Figure 2 .  Heat map showing conditional analysis of association signals at  ABCB11 locus using the same technique as  Figure 1 to identify whether multiple 
associations are present. 
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 FGF19 secretion and signaling represents a key part of the enter-
ohepatic circulation by regulating CYP7A1 expression ( 40 ), and 
hence this was a plausible candidate locus for ICP. However, com-
mon variation around this locus does not seem to play a major role 
in disease susceptibility in our cohort. 
 It is important to recognize however that weaker associations at 
these other candidate loci may be identifi ed by future studies with 
much larger cohorts. 
 In addition to the genetic susceptibility to ICP, evidence is accu-
mulating for the involvement of other factors in this complex 
condition. During the third trimester when the disease usually 
presents, circulating levels of reproductive hormones are at their 
highest and recent work has identifi ed progesterone metabolites as 
capable of reducing bile acid uptake in hepatocytes, thereby having 
a potential role in ICP  49 – 51) . Estrogen metabolites have also been 
implicated ( 52 ). Environmental factors have also been identifi ed 
that may play a role, including seasonal variation and selenium lev-
els ( 53 ). A proposed disease mechanism is that altered concentra-
tions of specifi c hormone metabolites can unmask the disease in 
genetically susceptible individuals. 
 Th e identifi cation of a role for common variation in  ABCB4 and 
 ABCB11 in the etiology of ICP is of relevance in a clinical context. 
Th e condition has a spectrum of severity. At present, the princi-
pal way the severity of maternal disease is classifi ed is in terms of 
the maternal serum bile acid level. ICP typically presents in the 
third trimester of pregnancy and resolves aft er delivery of the baby. 
Approximately 20 % of cases have early-onset disease ( 10 ) and a 
similar proportion of cases have associated biliary diseases when 
they are not pregnant, ( 54 ) e.g., cholelithiasis. Although there are 
studies that demonstrate an association between the level of serum 
bile acids and rates of adverse pregnancy outcome  (8,10), the rela-
tionships are not straightforward. It will be of value to clinicians 
managing this condition for future studies to establish whether 
specifi c genotypes in the mother are associated with an increased 
risk of specifi c clinical features of ICP, including severity of dis-
ease and associated maternal and off spring diseases. Furthermore, 
patients with  ABCB4 mutations respond to ursodeoxycholic acid, 
and hence it is feasible that the SNPs reported in this study will be 
associated with treatment response. Th is study was not designed 
to evaluate treatment response, and hence it was not possible to 
establish whether this is the case. At present, it is also not known 
fi ndings have important implications as studies in other popula-
tions have postulated roles for the 444A polymorphism in drug-
induced cholestasis ( 46 ) and in hepatitis C-related cirrhosis ( 47 ). 
Given that the SNP rs7577650 is intronic, and that the regression 
analysis shows it to be driving the association seen with 444A, it 
is possible that the underlying functional variation has yet to be 
identifi ed. Deep resequencing of this region using next-genera-
tion platforms will be necessary to identify the catalog of varia-
tion around the identifi ed associations and identify the underlying 
causative risk alleles, for both the rs7577650 / 444A signal and the 
new independent signal we have identifi ed, rs3815676. 
 Genetic variation around the multidrug resistance-related pro-
tein  ABCC2 represents an attractive candidate for ICP susceptibil-
ity because of the localization and function of the protein ( 35 ). A 
previous study of a South American population proposed an asso-
ciation with ICP ( 36 ), but this was not replicated in a European 
Caucasian population ( 46 ). By saturating the genomic region of 
 ABCC2 with tagging SNPs in our larger cohort ( n  =  563 vs. 70 in 
the initial report) we have shown that common variation of this 
transporter does not play a major role in ICP susceptibility in our 
Caucasian cohort (including the SNP identifi ed in the initial report 
(rs3740066)). 
 Th e causative gene for PFIC1 / BRIC1 was also included in our 
analysis. Previous small studies have reported heterozygous SNPs 
of  ATP8B1 in ICP cases ( 32,33 ) but have not demonstrated con-
clusive functional eff ects of these variants in  in vitro studies ( 48 ). 
Our analysis has excluded common variation around this locus as 
having a large role in the disease. 
 We previously identifi ed genetic variation at the  NR1H4 (far-
nesoid-X receptor) locus in our ICP cohort ( 37 ) and demonstrated 
functional eff ects for some of these variants. However, the popula-
tion frequencies were very low in both cases and controls. In the 
expanded cohort used in this study, the frequency of these variants 
has not changed signifi cantly in cases or controls. Th us, common 
genetic variation around FXR is unlikely to play a major role in the 
etiology of ICP. A weakness of this study is that the cohort is not 
suffi  ciently large to identify rare variants that confer susceptibility 
to ICP, despite being the largest available cohort to our knowledge. 
Th is is exemplifi ed by the NR1H4 results that confi rmed the pres-
ence of rare functional variants but did not establish these variants 
as common susceptibility alleles for ICP. 
 Table 2 .  Second cohort analysis and combined analysis of ICP associations (trend test  P values) 
 dbSNP identifi er  Original cohort  Second cohort  Combined cohort ( n =790)  Combined MAF (ICP)  MAF (C)  OR (95 % CI) 
 ABCB11 
  rs3815676  5.8 × 10   −  4  4.6 × 10   −  4  4.6 × 10   −  8  0.013  0.049  3.79 (2.30 – 6.26) 
  rs7577650  1.8 × 10   −  4  1.9 × 10   −  2  2.9 × 10   −  6  0.32  0.40  1.46 (1.25 – 1.70) 
 ABCB4 
  rs2109505  4.6 × 10   −  7  3.3 × 10   −  6  1.6 × 10   −  11  0.11  0.20  2.06 (1.67 – 2.54) 
 C, control; CI, confi dence interval; dbSNP, single-nucleotide polymorphism database; ICP, intrahepatic cholestasis of pregnancy; MAF, minor allele frequency; OR, odds 
ratio. 
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whether mutation screening is justifi ed in ICP. However, with the 
emerging use of next-generation sequencing technology in the 
clinic, it will be valuable for future studies to evaluate whether 
women with early-onset severe disease, particularly if they have a 
family history of ICP or related biliary disease, have mutations in 
 ABCB4 or  ABCB11 . 
 We have identifi ed population risk alleles for ICP in the two 
genes primarily responsible for bile formation; the phosphatidyl 
choline fl oppase  ABCB4 (MDR3) and the bile salt export pump 
 ABCB11 . Th e identifi cation of the functional variants that underlie 
these association signals will lead to a greater understanding of the 
mechanisms responsible for susceptibility to this cholestatic dis-
ease of pregnancy. 
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 Study Highlights 
 WHAT IS CURRENT KNOWLEDGE 
 3 Intrahepatic cholestasis of pregnancy (ICP) is a complex 
disease with a signifi cant genetic component. 
 3 Rare mutations of hepatobiliary transporters have been 
identifi ed. 
 3 Less is known about common variants and disease risk, 
although the  ABCB11 444A allele has been implicated. 
 WHAT IS NEW HERE 
 3 Three common variants in  ABCB11 and  ABCB4 have a 
signifi cant impact on ICP susceptibility. 
 3 In contrast to earlier studies, the lead association signal at 
 ABCB11 is rs7757650. 
 3 An independent association has been identifi ed at this 
locus, contributing separately to risk.  
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